Treatment of renal osteodystrophy

被引：1
作者：
Gal-Moscovici A. [1 ,2 ]
Sprague S.M. [2 ,4 ]
Lerma E.V. [3 ]
机构：
[1] Hadassah Hospital Medical Center, Hebrew University, Ein Keren, Jeruslaem
[2] Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, IL
[3] Section of Nephrology, University of Illinois at Chicago, College of Medicine/Associates in Nephrology, Chicago, IL
[4] Evanston, IL 60201
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2007年 / 5卷 / 1期
关键词：
Cinacalcet; Parathyroidectomy; Phosphate binders; Renal osteodystrophy; Vitamin D receptor agonist;
D O I：
10.1007/BF02736669
中图分类号：
学科分类号：
摘要：
Chronic kidney disease (CKD) is accompanied by disturbances in calcium, phosphate, vitamin D, and parathyroid hormone (PTH) homeostasis known to play an important role in the pathophysiology of renal osteodystrophy. Increased cardiovascular morbidity and mortality rate among CKD patients, correlates with these disturbances in bone and mineral metabolism and underscores the nephrologist's concern about the effectiveness of the present therapeutic approach. Treatment directed to normalize the calcium/phosphate, vitamin D and PTH abnormalities may adversely affect endothelial, vascular and bone cells activity. This article discusses the therapeutic approaches focuses for renal osteodystrophy. © Copyright 2007 by Humana Press Inc. All rights of any nature whatsoever reserved.
引用
收藏
页码：27 / 38
页数：11
相关论文
共 115 条
[41]  
Hou S.H., Zhao J., Ellman C.F., Et al., Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate, Am J Kidney Dis, 18, pp. 217-224, (1991)
[42]  
Achinger S.G., Ayus J.C., The role of daily dialysis in the control of hyperphosphatemia. Kidney Int (Suppl), pp. 28-32, (2005)
[43]  
Emmett M., Sirmon M.D., Kirkpatrick W.G., Et al., Calcium acetate control of serum phosphorus in hemodialysis patients, Am J Kidney Dis, 17, pp. 544-550, (1991)
[44]  
Mai M.L., Emmett M., Sheikh M.S., Et al., Calcium acetate, an effective phosphorus binder in patients with renal failure, Kidney Int, 36, pp. 690-695, (1989)
[45]  
Pflanz S., Henderson I.S., McElduff N., Jones M.C., Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis, Nephrol Dial Transplant, 9, pp. 1121-1124, (1994)
[46]  
Schaefer K., Scheer J., Asmus G., Et al., The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study, Nephrol Dial Transplant, 6, pp. 170-175, (1991)
[47]  
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic hemodialysis patients, J Am Kidney Dis, 42, SUPPL. 3, (2003)
[48]  
Salusky I.B., Foley J., Nelson P., Goodman W.G., Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease, N Engl J Med, 324, pp. 527-531, (1991)
[49]  
Hsu C.H., Are we mismanaging calcium and phosphate in renal failure?, Am J Kidney Dis, 29, pp. 641-649, (1997)
[50]  
Salusky I.B., Ramirez J.A., Oppenheim W.L., Et al., Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD, Kidney Int, 45, pp. 253-258, (1994)
12345678910